Axolotl Biologix CSO Recognized Among Arizona's Top Healthcare Leaders

Axolotl Biologix CSO Recognized Among Arizona’s Top Healthcare Leaders

Chief Science Officer Selected For 2019 Researcher of the Year

 

Phoenix, AZ (May 22, 2019) - Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce its Chief Science Officer, Robert Kellar, Ph.D., has been recognized as one of Arizona’s top healthcare leaders. Arizona Business Magazine’s editorial board selected Kellar as one of 2019’s Healthcare Researchers of the Year.

The business magazine called Kellar a highly respected biotechnology innovator, listing his regenerative medicine technologies, Axolotl Shot and Axolotl DualGraft, as evidence of his valued contributions to the field. These technologies enable the body’s tissues and cells to repair and regenerate, giving patients new options to improve outcomes without the costs and discomforts of surgery.

“I am honored to be recognized along with this highly esteemed group of researchers who are dedicated to shaping the future of healthcare in Arizona,” said Kellar. “I have made it my life’s work to research and develop innovative therapeutic options that disrupt traditional treatments and I am grateful to Axolotl Biologix for giving me an incredible team that has accomplished so much, so quickly.”  

Kellar has spent nearly 20-years developing, manufacturing, and commercializing medical devices and technologies both as a researcher and professor. He’s currently at Northern University Arizona serving as an Associate Professor in the Center for Bioengineering Innovation, Co-Director of the Bioengineering Ph.D. Program, Co-Director for the Imaging & Histology Core Facility (IHCF), and an adjunct faculty member in Mechanical Engineering.

Axolotl Biologix is a national leader in regenerative medicine with liquid and membrane allograft products to help promote repair and regeneration of damaged tissues. Kellar’s team also created Axolotl Ambient™, the first commercially available room temperature regenerative fluid product that is now available through federal agencies such as the Veterans Administration and Indian Health Services.

Arizona Business Magazine named Kellar among the five Healthcare Researchers of the Year in its May issue honoring 2019 Healthcare Leaders of the Year. The other honorees are Marc Jacofsky, Ph.D., Chief Science Officer for The CORE Institute, Akinlolu O. Ojo, M.D., Associate Vice President for Clinical Research and Global Health Initiatives at the University of Arizona Health Sciences, Sunil Sharma, M.D., Deputy Director of Clinical Sciences for Translational Genomics Research Institute and Kris Vijay, M.D., Medical Director for the Institute of Congestive Heart Failure at Abrazo Arizona Heart Hospital.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

###

 

Media Contact:

Josh Weiss

10 to 1 Public Relations

josh@10to1pr.com

480-789-0743

 

Laura Slawny

10 to 1 Public Relations

laura@10to1pr.com

480-868-9423 

Private Equity Firm Purchases Phoenix-based Regenerative Medicine Company

Axolotl Biologix

Company Plans to Initiate Clinical Trials and FDA Approvals of Its Products

Phoenix, AZ (May 8, 2019) – A Texas private equity firm announced the purchase of Axolotl Biologix, Inc. a biotechnology leader in regenerative medicine. Terms of the deal were not disclosed.

With the purchase, Axolotl board member Gary Lauterbach accepted the role of Interim CEO as Phil Larson exits. Other staff, including Chief Science Officer Robert Kellar, Ph.D. and Senior Director of Research & Development Robert B Diller, Ph.D., will remain as the company expects to initiate FDA clinical trials of its current products and others under development.

“The investment by the private equity company allows Axolotl Biologix to execute a more long-term strategy which includes conducting FDA approved clinical trials to further grow acceptance and adoption of our regenerative products,” said Lauterbach. “The team and products at Axolotl are top notch, and we’re very excited about both the short and long-term opportunities awaiting Axolotl Biologix.”

Gary Lauterbach’s goal is to expand distribution of Axolotl products beyond the 500 offices and clinics across the U.S. already utilizing the company’s products and secure new partners as a GSA Contractor.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

###

Media Contact:

Josh Weiss

10 to 1 Public Relations josh@10to1pr.com

480-789-0743

Laura Slawny

10 to 1 Public Relations laura@10to1pr.com

480-868-9423

Glendale Biotechnology Students Tour Axolotl Biologix Laboratory

Glendale Biotechnology Students Tour Axolotl Biologix Laboratory  

Phoenix Company Opens Doors To Encourage STEM Careers

 

Phoenix, AZ (February 21, 2019)Axolotl Biologix, a biotechnology leader in regenerative medicine, shared some of the secrets of its success with Glendale Community College’s top STEM students. The Phoenix company welcomed members of GCC’s Biotechnology Club to explain regenerative medicine and how they research, develop and manufacture regenerative products from human cell and tissue technologies for medical applications.

Axolotl Biologix is one of only two biotechnology companies selected this semester to inspire students majoring in biotechnology, cell/molecular biology, research and pre-med.

“Everyone at Axolotl Biologix loved speaking with these bright students to explain how our work is shaping the future of medicine by focusing on expanding the body’s ability to regenerate,” said Dr. Robert Diller, Senior Director of Research and Development of Axolotl Biologix. “It was inspiring to meet these young people and hopefully spark an idea that will lead them to discover to the world’s next great medical technology.”

 GCC’s Biotechnology Club conducts independent research, tours biotech facilities, participates in science fairs and competitions, and meets with industry professionals.

“After touring Axolotl Biologix, it stapled the company in our eyes as being one of the greatest facilities we have toured as it was clean, organized, focused and its leaders were quite humble,” said Christian Topete, President of the Biotechnology Club at GCC. “Axolotl Biologix really resonated with us as a group in that the company’s mission is to help those in need.”

 

Axolotl Biologix offers regenerative medicine treatment applications with clinical benefits known to stimulate cellular growth and repair of damaged cells and tissues.

 

In January, the General Services Administration’s (GSA) added Axolotl Biologix to the Federal Supply Schedule (FSS), to make its products available through the Veterans Administration and Indian Health Services. Government Marketing & Procurement, LLC assisted Axolotl Biologix in the process. 

 

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

20190208_145205 (2).jpg

Axolotl DualGraft™ Press Release

Axolotl Biologix Launches New DualGraft™ For Faster Healing

Regenerative Medicine Patch Advances Wound Repair

 

Phoenix, AZ (January 23, 2018) – To help physicians facilitate wound healing, Axolotl Biologix, a biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl DualGraft™, a bi-layered human amnion membrane patch that serves as a barrier to protect wounds while advancing skin repair and reconstruction.

Axolotl’s DualGraft promotes healing of damaged tissue by using amniotic components to create a biological scaffolding which stimulates cells to repair themselves. This 3-dimensional extracellular matrix scaffold encourages cell migration and proliferation needed for healing.

 

DualGraft™ also helps to establish an environment in the wound to lower the growth of bacteria and reduce the rate of infection in chronic wounds, such as diabetic ulcers. Since it is conveniently packaged as a terminally irradiated, dehydrated allograft, it can be stored at room temperature and applied in a clinical setting.

 

“We our proud to offer physicians our new Axolotl DualGraft to help promote healing in wounds and improve patient outcomes in a number of clinical applications,” said Dr. Robert Kellar, Chief Science Officer of Axolotl Biologix. “DualGraft is the newest addition to our line of products in the space of regenerative medicine.”

 

“Research has demonstrated amniotic membrane products, like DualGraft, have clinical benefits that will help physicians and wound care specialists,” said Dr. Robert Diller, Senior Director of Research. “This is only the beginning as we research and develop new technologies to help people age without losing their ability to stay active.”

 

Amnion membrane used in DualGraft™ are derived from the amniotic lining of the placenta following a scheduled cesarean section. The donated amniotic membrane is recovered and processed aseptically in accordance with all FDA guidelines and quality assurance standards in a controlled environment.

 

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com

###

Media Contact:

Josh Weiss

10 to 1 Public Relations

josh@10to1pr.com

480-789-0743

 

Laura Slawny

10 to 1 Public Relations

laura@10to1pr.com

480-868-9423

 

GSA Press Release

Axolotl Biologix Products Approved and Added to the General Services Administration’s Federal Supply Schedule

Award Allows the VA, Indian Health Services and Other Federal Agencies to Order and

Prescribe Axolotl Biologix Products

Phoenix, AZ (January 14, 2019) - Axolotl Biologix, a biotechnology leader in regenerative

medicine, is proud to announce that the General Services Administration (GSA) has added

Axolotl Biologix’s products to the Federal Supply Schedule (FSS).

The GSA award will allow physicians and staff of federal agencies, such as the Veterans

Administration and Indian Health Services, to order Axolotl Biologix products when seeking

remedies to promote repair or regeneration of damaged tissues. Products now available through

the FSS to address these issues include Axolotl Biologix’s lines of regenerative fluid and

membrane allografts.

“We are thrilled that Axolotl Biologix products have been added to the GSA’s Federal Supply

Schedule which allows government agencies to order our products as they develop treatment

plans for their patients,” said Phillip Larson, President of Axolotl Biologix. “Approval and

inclusion in the FSS will provide patients and their physicians additional care options.”

Axolotl Biologix currently has three products available on the GSA’s FSS and have begun the

process to add additional products in the months and years ahead. Its liquid allograft products

come in both cryopreserved and ambient temperatures giving medical facilities more flexibility

to have products on-hand as needed, while Axolotl Biologix’s membrane allograft products

assist with wound care.

GMP- Government Marketing & Procurement, LLC assisted Axolotl Biologix in the process to be added to the GSA’s FSS.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through

research, technology and clinical application. Axolotl Biologix is expanding the human body’s

ability to regenerate by developing and manufacturing regenerative human cell and tissue

medical technologies that are disrupting traditional, more invasive, painful and expensive

treatment protocols. For more information, visit www.axobio.com

###

Media Contact:

Josh Weiss

10 to 1 Public Relations

josh@10to1pr.com

480-789-0743

Laura Slawny

10 to 1 Public Relations

laura@10to1pr.com

480-868-9423

Axolotl Shot™ Press Release

Axolotl Biologix Launches New Axolotl Shot™ For Wound Care

Pre-Loaded Regenerative Medicine Syringe Saves Doctors Time and Money

 

Phoenix, AZ (Dec. 5, 2018) - Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl Shot™, an ambient temperature regenerative fluid preloaded into a syringe for ease of use by physicians.

Axoltol Biologix is the first to market a preloaded syringe containing a regenerative fluid that is manufactured using the proprietary BioSym™ process to yield growth factors and cytokines known to stimulate cellular growth and repair. It offers significant therapeutic benefits to help facilitate repair and regeneration of damaged cells and tissues


 

“Our new Axolotl Biologix treatment option uses the latest advances in biotechnology to improve patient outcomes while making it more convenient for physicians,” said Dr. Robert Kellar, Chief Science Officer.  “The Axolotl Shot is preloaded in 1mL and 2mL volumes, terminally irradiated for use in surgical applications, and since it can be stored at room temperature there is no storage concerns or down time waiting for product to thaw.”

 

This new option benefits consumers because it can be applied during a same-day outpatient visit, helping patients avoid the costs, pain and downtime associated with surgery.

“Axolotl Biologix is excited to introduce the Axolotl Shot which has potential clinical benefits in a variety of applications that will help physicians, orthopods, and wound care specialists save time and money treating patients,” said Phillip Larson, President of Axolotl Biologix.

Axolotl Shot is a regenerative fluid derived from the amniotic components of the placenta to promote regeneration and repair of damaged or degenerated tissues. Donor tissue is recovered and processed aseptically in accordance with all FDA guidelines and quality assurance standards in a controlled environment.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com